Actively Recruiting
Phase 1 Trial Evaluating Safety and Pharmacology of VK2735 in Adults with Obesity Without Other Health Conditions
Led by Viking Therapeutics, Inc. · Updated on 2026-09-24
270
Participants Needed
2
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase 1, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of VK2735 in adults who are obese with a BMI of 30 kgm2 or higher and do not have other medical conditions. The study aims to understand how VK2735 behaves in the body and its safety profile in this specific group. The study involves approximately 270 adult participants divided into two parts, Part A and Part B. Participants in Part A are randomized equally into 12 treatment groups to receive one of 11 VK2735 dose regimens or a matching placebo, while Part B includes 6 treatment groups with four VK2735 dose regimens or placebo. Each part consists of two treatment periods lasting 21 weeks and 12 weeks, during which participants may receive different dosing schedules and routes of VK2735 administration, including subcutaneous injections or oral doses weekly, every other week, or monthly. Participants will be closely monitored throughout the study for safety and tolerability over 33 weeks. Researchers will also evaluate how the drug is processed in the body over 38 weeks. Assessments include physical exams, laboratory tests, and adherence to contraceptive guidelines. The study lasts until July 2027, and participants will have regular visits to track their health and responses to the drug or placebo during the treatment periods.
CONDITIONS
Brief Title
A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities
Research Team
H
Hubert C Chen, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here